Journal of the American Academy of Dermatology
Volume 63, Issue 2 , Pages 228-234 , August 2010

Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept

  • Robert Bissonnette, MD, FRCPC

      Affiliations

    • Innovaderm Research Inc, Montreal, Quebec, Canada
    • Corresponding Author InformationCorrespondence to: Robert Bissonnette, MD, Innovaderm Research Inc, 1851 Sherbrooke est, Bureau 502, Montreal, Quebec, H2K 4L5, Canada.
    • ,
  • Chantal Bolduc, MD, FRCPC

      Affiliations

    • Innovaderm Research Inc, Montreal, Quebec, Canada
    • ,
  • Yves Poulin, MD, FRCPC

      Affiliations

    • Centre de Recherche Dermatologique du Québec Métropolitain, Quebec, Canada
    • ,
  • Lyn Guenther, MD, FRCPC

      Affiliations

    • Guenther Dermatology Research Centre, London, Ontario, Canada
    • ,
  • Charles W. Lynde, MD, FRCPC

      Affiliations

    • Lynderm Research, Markham, Ontario, Canada
    • ,
  • Catherine Maari, MD, FRCPC

      Affiliations

    • Innovaderm Research Inc, Montreal, Quebec, Canada

,Accepted 25 August 2009.

References 

  1. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005;52:425–433
  2. Bissonnette R. Etanercept for the treatment of psoriasis. Skin Therapy Lett. 2006;11:1–4
  3. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–2022
  4. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304–1312
  5. Menter A, Tyring S, Gordon K, Kimball A, Leonardi C, Langley R, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–115
  6. Report of the Dermatologic and Opthalmic Drugs Advisory Committee 49th meeting, open session. Gaithersburg, Md: US Food and Drug Administration; March 1998. Available at: http://www.fda.gov/ohrms/dockets/ac/98/transcpt/3402t2.rtf. Accessed October 21, 2009.
  7. Guenther L, Langley RG, Shear NH, Bissonnette R, Ho V, Lynde C, et al. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian psoriasis expert panel. J Cutan Med Surg. 2004;8:321–337
  8. Langley RG, Ho V, Lynde C, Papp KA, Poulin Y, Shear N, et al. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches. J Cutan Med Surg. 2006;9(suppl):18–25
  9. Menter A, Gotleib A, Feldman SR, Van Vorhees AS, Leonard CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1; overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850
  10. Saurat J, Stingl G, Dubertret L, Papp K, Langley R, Ortonne J, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558–566
  11. Haitz K, Kalb R. Infliximab in the treatment of psoriasis in patients previously treated with etanercept. J Am Acad Dermatol. 2007;57:120–125
  12. Papoutsaki M, Chimenti M-S, Costanzo A, Talamonti M, Zangrilli A, Giunta A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol. 2007;57:269–275
  13. Yip L, Harrison S, Foley P. From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis. Australas J Dermatol. 2008;49:152–155

 Supported by Innovaderm Research Inc and an investigator grant from Abbott Laboratories.

 Disclosure: Dr Bissonnette has been a speaker, consultant, investigator, and/or advisory board member for Abbott, Amgen-Wyeth, Astellas-Pharma, Celgene, Centocor, EMD Serono, Galderma, Isotechnika, Leo Pharma, MedImmune, Ortho Biotech, Pfizer, and Schering-Plough Canada. He has received compensation in the form of grants and/or honoraria from these companies. Dr Bolduc has been a speaker, consultant, investigator, or advisory board member for Leo Pharma, Abbott, Amgen-Wyeth, Centocor, MedImmune, and Schering-Plough Canada. She has received compensation in the form of grants and/or honoraria from these companies. Dr Guenther has been a speaker, consultant, investigator, and advisory board member for Abbott, Amgen, Astellas-Pharma, Centocor, EMD Serono, Leo Pharma, Ortho Biotech, Novartis, Schering-Plough, and Wyeth. Dr Lynde has acted as a speaker and consultant for Astellas-Pharma, EMD Serono, Schering-Plough Canada, Abbott, Leo Pharma, and Amgen and receives compensation in the form of grants and honoraria. Dr Maari has been a speaker, consultant, investigator, and/or advisory board member for Abbott, Amgen-Wyeth, Astellas-Pharma, Centocor, Galderma, MedImmune, Ortho Biotech, and Schering-Plough Canada. She has received compensation in the form of grants and/or honoraria from these companies. Dr Poulin has been a speaker, consultant, investigator, and/or advisory board member for Abbott, Amgen-Wyeth, Astellas-Pharma, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor, EMD Serono, Galderma, Ortho Biotech, and Schering-Plough Canada. He has received compensation in the form of grants and/or honoraria from these companies.

 Reprints not available from the authors.

PII: S0190-9622(09)01150-5

doi: 10.1016/j.jaad.2009.08.040

Journal of the American Academy of Dermatology
Volume 63, Issue 2 , Pages 228-234 , August 2010

Article Tools

* Image Usage & Resolution